Taiwan Ocular Inflammation Society Consensus Recommendations for the Management of Juvenile Idiopathic Arthritis Associated Uveitis
Purpose
This study aimed to develop a consensus guideline for the management of juvenile idiopathic arthritis-associated uveitis (JIAU) in Taiwan, taking into account the regional differences in the manifestation and epidemiology of the condition.
Methods
The formulation of a consensus guideline for JIAU was undertaken by the committee of the TOIS. Each recommendation was formulated based on a comprehensive evidence-based literature review and the clinical experience of experts, and was graded using the Oxford Centre for Evidence-Based Medicine's "Levels of Evidence" guideline (March 2009). A modified Delphi process, including two-panel meetings, was used to develop the consensus guideline for JIAU.
Results
The TOIS consensus guideline proposed 10 recommendations in four categories: screening and diagnosis, treatment, complications, and monitoring. These recommendations covered 27 items and received more than 75% agreement from the panelists.
Conclusion
The TOIS has developed a consensus guideline for the management of Juvenile idiopathic arthritis-associated uveitis (JIAU) in Taiwan based on comprehensive evidence-based literature review, clinical experience, and the modified Delphi process. The guideline covers all aspects of JIAU management, including screening and diagnosis, treatment, complications, and monitoring. Early diagnosis and an efficient referral system between ophthalmologists and pediatric rheumatologists are critical for preventing irreversible visual impairment in children with JIAU. Balancing disease activity and medication use remains a key challenge in the management of JIAU, and further clinical studies are needed to address this issue.
Conflict of interest
No
Authors 1
Last name
CHEN
Initials of first name(s)
WD
Department
Department of Ophthalmology, Chang Gung Memorial Hospital
City
Chiayi
Country
Taiwan
This website uses cookies to ensure you get the best experience on our website.
Learn more